Nuvation Bio Inc. — Director's Dealing 2021

Feb 27, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Nuvation Bio Inc. (NUVB)
CIK: 0001811063
Period of Report: 2021-02-10

Reporting Person: Sharp Shalini (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-02-10	Class A Common Stock	M	25000	—	Acquired	25000	Direct
2021-02-10	Class A Common Stock	A	10000	$10	Acquired	35000	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-02-10	Class B Common Stock	$	M	25000	Disposed		Class A Common Stock (25000)	Direct

Footnotes

F1: Each share of Class B Common Stock owned prior to the consummation of the Agreement and Plan of Merger, dated as of October 20, 2020, by and among Panacea Acquisition Corp. ("Panacea"), Panacea Merger Subsidiary Corp., a direct, wholly-owned subsidiary of Panacea ("Merger Sub"), and Nuvation Bio Inc. ("Legacy Nuvation") pursuant to which, as a result of a merger between Legacy Nuvation and Merger Sub, Legacy Nuvation became a direct, wholly-owned subsidiary of Panacea, which subsequently changed its name to Nuvation Bio Inc. (such transaction, the "Business Combination"), was converted into one share of Class A Common Stock; the Class B Common Stock was convertible at any time at the election of the holder (or would have automatically converted at the time of the issuer's initial business combination if not yet converted at such time) with no expiration date.

F2: Acquired pursuant to one of a number of subscription agreements that Panacea entered into with various investors pursuant to which such investors agreed to purchase, immediately prior to the closing of the Business Combination, an aggregate of 47,655,000 shares of Class A Common Stock at a price of $10.00 per share.